BRIEF published on 07/11/2024 at 13:05, 1 year 7 months ago CureVac met à jour les dates des procès pour les litiges en matière de brevets contre Pfizer/BioNTech CureVac Contentieux Des Brevets Pfizer/BioNTech Dates Du Procès Mise À Jour Juridique
PRESS RELEASE published on 07/11/2024 at 13:00, 1 year 7 months ago CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech CureVac provides trial date updates for patent litigation against Pfizer/BioNTech in multiple geographies, including the U.S., UK, and Germany BioNTech CureVac Patent Litigation Pfizer Trial Dates
BRIEF published on 07/03/2024 at 08:17, 1 year 7 months ago CureVac Announces Strategic Restructuring to Focus on High-Value mRNA Opportunities Licensing Agreement MRNA Technology Oncology Research Strategic Restructuring Workforce Reduction
BRIEF published on 07/03/2024 at 08:17, 1 year 7 months ago CureVac annonce une restructuration stratégique pour se concentrer sur les opportunités d'ARNm de grande valeur Recherche En Oncologie Technologie ARNm Restructuration Stratégique Réduction Des Effectifs Contrat De Licence
BRIEF published on 07/03/2024 at 08:14, 1 year 7 months ago GSK and CureVac to Restructure Collaboration into New Licensing Agreement Licensing Agreement GSK CureVac MRNA Vaccines
BRIEF published on 07/03/2024 at 08:14, 1 year 7 months ago GSK et CureVac vont restructurer leur collaboration dans le cadre d'un nouvel accord de licence GSK CureVac Vaccins Contrat De Licence ARNm
PRESS RELEASE published on 07/03/2024 at 08:12, 1 year 7 months ago CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities CureVac initiates strategic restructuring to focus on high-value mRNA pipeline opportunities, including workforce reduction and new GSK agreement Oncology Strategic Restructuring CureVac MRNA Pipeline GSK Agreement
PRESS RELEASE published on 07/03/2024 at 08:09, 1 year 7 months ago GSK and CureVac to Restructure Collaboration into New Licensing Agreement GSK and CureVac restructure collaboration into new licensing agreement for mRNA vaccines development, manufacturing, and commercialization globally Licensing Agreement Collaboration GSK MRNA Vaccines CureVac
BRIEF published on 06/24/2024 at 22:10, 1 year 8 months ago CureVac Announces Voting Results of General Meeting Annual General Meeting Voting Results Board Appointments CureVac MRNA
BRIEF published on 06/24/2024 at 22:10, 1 year 8 months ago CureVac annonce les résultats du vote de l'assemblée générale Assemblée Générale Annuelle Nominations Au Conseil CureVac Résultats Du Vote ARNm
Published on 02/27/2026 at 22:00, 4 minutes ago MWC 2026: Amdocs Collaborates with Google Cloud to Accelerate AI Adoption and Power the Agentic Telco Contact Center
Published on 02/27/2026 at 17:45, 4 hours 19 minutes ago Sparta Capital Ltd. Announces Filing of Annual Financial Statements
Published on 02/27/2026 at 17:41, 4 hours 23 minutes ago Nepra Foods Inc. Achieves First Quarterly Net Income in Company History; Reports Financial Results for the Quarter Ending December 31, 2025, Revenue Increases 51% to $5,973,147, Gross Profit Rises to $1,855,624 (31.1% Margin), Net Income of $84,966
Published on 02/27/2026 at 16:00, 6 hours 4 minutes ago Trans Canada Gold Announces Plans for Exploration and Drilling on its Harrison Lake Gold Project, Lays Out Detailed 2026 Drilling Program Targeting Gold
Published on 02/27/2026 at 14:30, 7 hours 34 minutes ago Solitario Attending PDAC 2026 at Booth 2422A and Participating in One-on-One Meetings
Published on 02/27/2026 at 19:30, 2 hours 34 minutes ago EUROPLASMA: Modification des caractéristiques des tranches 22 et 23 d’OCABSA
Published on 02/27/2026 at 17:59, 4 hours 5 minutes ago EQS-Adhoc: 4finance completes sale of TBI Bank to Advent International
Published on 02/27/2026 at 18:02, 4 hours 1 minute ago AXA: Execution of a share repurchase agreement in relation to AXAs share buy-back program of up to Euro 1.25 billion
Published on 02/27/2026 at 18:02, 4 hours 1 minute ago AXA: Conclusion d’une convention de rachat d’actions dans le cadre du programme de rachat d’actions d’AXA
Published on 02/27/2026 at 17:45, 4 hours 19 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2025
Published on 02/27/2026 at 17:45, 4 hours 19 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of January 31, 2026
